BIVI Biovie Inc
Company Analysis
Latest News
🟢 Biovie is trading 6% up — no confirmed catalyst
Biovie is trading at $1.41, up 6.02%, with no confirmed catalyst identified for the October 27 move. - On October 26, BioVie announced it was invited to...
🟢 Biovie is trading 5% up in pre-market
Biovie is trading at $1.40, up 5.26%, with no confirmed catalyst identified for the pre-market move. - An October 26 announcement said BioVie was invited to...
🟢 Biovie is trading 5% up today with no confirmed catalyst
Biovie is trading 5% higher at $1.30 on October 26, 2026; available reporting does not establish a reason for the move. - Broader markets are higher: the S&P...
🔴 Biovie is trading 6.25% down in pre-market
Biovie is trading down 6.25% in pre-market at $1.20, and the reason for the decline remains unclear. - The price compares with the October 22 close of $1.28. -...
🟢 Biovie is trading 9.5% up in pre-market alongside XBI's 3.64% pre-market gain
Biovie is trading at $1.38, up 9.52%, alongside broader biotech-sector strength; that context does not establish the cause of the gain. - XBI is up 3.64%...
🔴 Biovie is trading 7.26% down on October 21, 2026 with no confirmed company-specific catalyst
Biovie is trading 7.26% down at $1.15, with no confirmed company-specific catalyst identified for the October 21 decline. - On October 20, the company...
🔴 Biovie is trading 5.84% down on October 20 with no clear catalyst identified
Biovie is trading at $1.29, with a -5.84% change and no clear catalyst identified. - No company-specific announcement dated October 20 was identified. BioVie’s...
🔴 Biovie is trading 9.23% down in pre-market as biotech ETF XBI falls 3.65%
Biovie is trading $1.24, down 9.23% in pre-market on October 20, amid biotech sector weakness. - The previous close was $1.37; XBI was down 3.65%...
Biovie's Long COVID Trial Missed Its Big Moment — Can Subgroup Data Alone Justify What Comes Next?
Shares of BioVie Inc. jumped 10.8% to $1.33 as the micro-cap biotech presented Phase 2 data from its Long COVID trial at the American Neurological Association...
🟢 BioVie surges 10.83% on promising Phase 2 Long COVID subgroup results
BioVie is trading at $1.33 (+10.83%) following promising Phase 2 Long COVID results. - On October 19, Biovie presented data at the American Neurological...
🟢 Biovie is trading 5.83% up; no confirmed catalyst identified
Biovie is trading at $1.27, up 5.83%, with no confirmed catalyst identified. - On October 19, Biovie announced presentation of Phase 2 Long COVID study...
🟢 Biovie is trading 7.5% up in pre-market without a confirmed catalyst
Biovie is trading 7.5% up at $1.29 before the October 19, 2026 market open; no fresh company announcement or confirmed catalyst explaining the move was...
🟢 Biovie is trading 7% up on October 16, 2026 with no confirmed catalyst
Biovie is trading at $1.21, up 7.08%, with no company-specific catalyst confirmed for the October 16 move. - The latest company announcement, dated October...
🔴 Biovie is trading 5% down in pre-market — no catalyst confirmed
Biovie is trading 5.17% down at $1.10 in pre-market, with no specific catalyst confirmed. - No company announcement dated October 15 was listed. The latest...
🟢 Biovie is trading 7.8% up in pre-market ahead of Phase 2 study presentations
Biovie is trading at $1.25, up 7.76% pre-market; reporting does not link the rise to the announcement. - On October 14, 2026, Biovie announced two Phase 2...
🔴 Biovie is trading 6.8% down with no clear company-specific catalyst
Biovie is trading 6.8% down at $1.23 on October 13, 2026, with no clear company-specific catalyst identified. - BioVie’s investor-news page lists its latest...
🔴 Biovie is trading 5.8% down; catalyst remains unclear
Biovie is trading 5.8% down at $1.31 on October 12, 2026, with no clear company-specific catalyst identified. - The company’s investor-news page lists its...
🟢 Biovie is trading 5% up — cause remains unclear
Biovie is trading 5.47% up at $1.35 on October 9, 2026; the cause remains unclear. - No clear company-specific announcement or event explaining the gain was...
🔴 Biovie is trading 5.7% down on October 8, 2026 amid biotech weakness, with no clear catalyst
Biovie is trading 5.7% down at $1.32, alongside biotech weakness and a broader risk-off backdrop. - Elevated Treasury yields are weighing on risk appetite;...
🟢 Biovie is trading 6.43% up in pre-market
Biovie is trading 6.43% up at $1.49, versus its October 7 close of $1.40; no confirmed company announcement explains the October 8 pre-market rise. - BioVie’s...